Frontotemporal
The latest sourced reporting on Frontotemporal from Dementias Today: dated, and plain about what the evidence does and does not show.
A narrative review published on October 20 inventories where generative AI already touches Alzheimer's work. The uses furthest along are the ones no family ever sees: synthetic notes, phenotype mining from visit records, and drafted summaries. None of it has been tested in a live clinic.
A new scoping review pulls 108 studies on gardens, green space and outdoor programs into one picture. What it shows is real. What it leaves blank matters just as much.
Nine Italian memory clinics signed up to test whether a structured daily diary of behaviour beats standard care at lightening the load on families. Three years after the trial was registered, the results have not appeared.
A peer reviewed protocol lays out a 160 person randomized trial testing whether a mobile app, Brain CareNotes, that structures what family care partners report about behavioral symptoms of Alzheimer's and related dementias eases caregiver burden and those symptoms. The trial is still enrolling; no effectiveness results exist yet.
A small randomized trial of 36 caregiver-dyads in South Korea found that a mobile app translating caregiver-logged behavior into individualized, nonpharmacological activity suggestions was associated with lower overall behavioral and psychological symptoms, less agitation and depression, better nighttime sleep efficiency, and higher caregiver confidence, researchers reported.
In a Taipei scanner, 31 healthy adults were given the same electric jolt over and over. What changed how much it hurt was not how reliable their expectation was, but how much feeling it carried. For anyone thinking about pain and dementia, that difference matters.
A multicenter European study put a finger prick against a needle in the arm, and asked whether a card of dried blood mailed at room temperature could carry the same signal. For people whose veins are hard to find, including adults with Down syndrome, the question is not academic.
At a cognitive neurology clinic, a voice AI ran the long history-taking interview while patients waited for their testing. A peer-reviewed SIGDIAL 2026 paper reports what it caught, and what it still cannot tell anyone.
A PLOS Biology study of 72 adults, published on 2 March 2026, separated the strength of a pain expectation from its certainty, and found each one riding a different alpha rhythm in the anticipating brain. Basic mechanism work in healthy volunteers, not a treatment, and not a dementia study.
A cluster-randomized trial in 38 primary care clinics is testing whether an alert built into the electronic health record can help clinicians catch cognitive impairment they might otherwise miss, with the first published results in on clinician confidence, not on diagnosis rates.
A pooled analysis of brain-scan data from 409 people finds that words alone and words paired with conditioning change pain-related brain activity in overlapping but partly different ways, a distinction researchers say matters for how future placebo-based protocols are designed and tested.
A February 2026 Nature review by Henrik Zetterberg and Barbara Bendlin gathers the scattered story of blood and spinal fluid tests across Alzheimer's and other neurodegenerative dementias, and shows plainly where the map runs out.
A UK feasibility study wore blinded Dexcom G7 sensors on 32 older inpatients with type 2 diabetes and cognitive impairment for up to 10 days, testing whether continuous glucose monitoring can be deployed on the ward at all, before any question of whether it changes outcomes.
A review in Alzheimer's & Dementia maps how falling NAD+ and the body's 24-hour timing machinery pull on each other in dementia. It is a map of mechanisms, not a treatment.
A plasma marker called eMTBR-tau243 tracks Alzheimer's tau tangles rather than amyloid. Three published cohorts say it works as a measure. None of them says yet who should be treated.
ClinicalTrials.gov now lists Alector and GSK's Phase 3 INFRONT-3 trial of the anti-sortilin antibody latozinemab as "Completed," a formal registry update dated January 6, 2026 that follows the sponsor's October 2025 disclosure that the drug raised a target biomarker but did not slow disease in people with FTD caused by a progranulin gene mutation.
An audit of records at one large academic health system found that a diagnosis of dementia or cognitive impairment barely moves the odds a caregiver has been granted shared access to a patient's electronic health record portal, a gap researchers say undercuts every other tool built on top of it.
A long-term follow-up of the DREAMS START trial found that sleep improvements in people with dementia were still detectable 24 months after the program began, though the family caregivers' own sleep did not improve.
A new scoping review catalogs 43 studies of AI tools built for family caregivers of people with Alzheimer's disease and related dementias, from robots to chatbots. The authors found a wide range of functions on offer and called for rigorous, long-term testing that so far has not been done.
Proceedings of the first EU-US CTAD Task Force on genetic therapies, published in the Journal of Prevention of Alzheimer's Disease, walk through what went wrong in adeno-associated virus trials for Alzheimer's and frontotemporal dementia: missed targets, dose-limiting nerve inflammation, and a delivery problem nobody has solved.
A Dutch laboratory trial found that openly telling healthy volunteers a device could not hurt them, paired with a symptom-reversing procedure, eased artificially induced pain sensitivity as well as or better than concealing that information. The method has not been tested in patients, older adults, or anyone with a dementia.
A 262-caregiver randomized trial of WeCareAdvisor, the web app that turns a caregiver's plain-language account of a behavior into a tailored, physician-shareable plan, found a modest but statistically significant drop in caregiver distress by three months. Two of its three prespecified primary measures, confidence and the behaviors themselves, showed no significant difference between groups.
A circuit-mapping study in mice found that a context paired with morphine later produced about half the drug's own pain relief, with the brain releasing its own opioids. A commentary in Current Biology says it is time to rethink what morphine's numbers in trials actually measure, including in studies of pain and agitation in dementia.
A newly published study protocol describes a three year effort in South Korea to follow community dwelling seniors with mild cognitive impairment using wrist actigraphy, sweat patch sampling and indoor sensors, alongside yearly home visits, with the goal of building machine learning models of who progresses to dementia.
A memory clinic team at the University of Virginia drafted a short survey to gauge how ready a care partner feels to plan ahead. The instrument exists on paper. It has not yet been given to a single caregiver in a validation study.
In a Padua laboratory, 102 young adults were handed sham lenses and a story about what they would do. The story alone moved their reading speed. Not their mood: their output.
Three months after opening the rewrite for public comment, HHS has formally issued its 2026 Update to the National Plan to Address Alzheimer's Disease and Related Dementias, restructuring federal priorities around risk reduction, research, care and family support.
A fresh census of frontotemporal lobar degeneration trials finds the field has more than tripled since this paper last checked, with drugs and brain stimulation now splitting the pipeline evenly, even as two closely watched gene therapies quietly closed their doors this year.
A lab study combining EEG, pupil tracking and behavioral testing found that when a sensory event matched what people expected, they judged its location faster, but recalled the exact spot less precisely, a pattern the researchers say reveals two separate brain processes, not one.
A nationwide study of more than 2,000 older insulin users with Alzheimer disease and related dementias found that those wearing a continuous glucose monitor had a 43 percent lower death rate and fewer hospital stays than those checking blood sugar with fingersticks, though several related safety measures did not reach statistical significance.
Governor Kathy Hochul has signed a law forcing New York's long-term care hotline, NY Connects, to actively point callers toward Alzheimer's and dementia programs rather than leaving them to ask. The catch: nothing changes for a full year.
In a 274-person trial spanning 43 countries, dementia caregivers who used a self-guided, chatbot-driven psychoeducation program called PDC30 reported less depression and less burden after one month than those left on a waiting list. No clinician ever entered the exchange.
A new legal analysis walks through every place in the world where voluntary assisted dying is lawful and finds that a dementia diagnosis, by itself, almost never clears the bar, even in the handful of countries that allow a person to request it in advance.
Across four hospitals and 70 clinics in Hawaii, an ambient AI scribe drafted more than 25,000 real visit notes in three months. It gave clinicians back time. Whether a caregiver's account arrives intact in the note is a question nobody has asked yet.
Interim data from Arrowhead Pharmaceuticals show an experimental RNA interference drug cut a tau marker in spinal fluid by more than seventy percent in healthy volunteers, the first sign that a single injection can carry the company's delivery technology into the brain. Whether that drop in a marker means anything for Alzheimer's disease has not yet been tested.
Twenty-two health and social care professionals across England describe, in a new qualitative study, how people with dementia who live alone with no family or friend nearby can vanish from the system's view at every stage, from the first missed sign to the day they go home from hospital with no one waiting.
Twenty-five people with nonfluent variant primary progressive aphasia, a disease with no approved treatment, took an experimental pill for twelve weeks. A blood marker of nerve damage fell. The company that makes the drug reported it. The finding is real, and it is also the first rung of a very long ladder.
A Lancet Psychiatry review maps the ways a clinician's wording shapes what a patient feels, and asks which of those ways survive telling the patient everything
A scoping review in Frontiers in Dementia went looking for every study in the past decade that fed magnetoencephalography data to machine learning for dementia risk. The count came back at fourteen. Here is what those papers reach, and where they stop.
The National Institute for Health and Care Research has extended its Policy Research Unit at the University of Exeter with 2 million pounds and two extra years, stretching its mandate past dementia and neurodegeneration to cover more of the neurological conditions families live with.
A new discussion paper from the FDA's Digital Health Center of Excellence sketches a way to grade generative AI tools by risk, but it never says whether software that turns a caregiver's daily notes into a clinician's summary counts as a medical device at all. The public has until October 19 to weigh in.
DemMA, published in the Findings of ACL 2026, puts a simulated person with dementia in the chair so trainees can practise the conversation: nine subtypes, nonverbal cues, 2,709 synthetic dialogues, and not one real patient in the data.
A JAMA audit of every AI device the FDA has authorized for Alzheimer's disease and related dementias found the paperwork behind them seldom names the patients the software learned from. Race and ethnicity appeared for at most one device per source.
A first-in-human trial at the University of California, San Francisco is imaging a transporter that sits almost entirely on astrocytes, the brain's housekeeping cells, to see whether their decline shows up before amyloid or tau does. So far, the only published results confirm the tracer is safe to give.
The Massachusetts House voted unanimously on July 29, 2026 to require acute care hospitals to notify a designated family member or caregiver soon after a dementia patient is admitted and again before discharge. The bill, which also expands diagnosis notification and creates a new MassHealth care coordination benefit, now heads to the Senate.
Governor Wes Moore has signed a law replacing Maryland's lone dementia director with a full state program, and ordered health officials to find out whether the state's clinicians are actually ready for the patients already walking into their offices.
At a Philadelphia dementia conference, AviadoBio reported that cerebrospinal progranulin climbed higher at higher doses of its experimental gene therapy for a genetic form of frontotemporal dementia, while a blood marker of nerve injury held steady or eased in patients followed for a year.
H.R.6130 would give Medicare, for the first time, legal authority to cover blood-based screening for Alzheimer's disease and related dementias. The bill sets January 1, 2028 as the earliest possible start date, a date that holds only if the measure becomes law.
A regional midterm review of the UN Decade of Healthy Aging finds that the share of countries in the Americas with a national long-term-care policy jumped from 61 percent to 88 percent since 2020, but the money and services to make those policies real have not kept pace, with direct consequences for how dementia care gets funded and staffed.
UK Research and Innovation has launched the Dementia Challenge, funding real-world NHS trials of faster MRI scans, blood tests and remote cognitive assessments, with a target of diagnosing 92% of referred patients within 18 weeks, up from about 60% today.
Wave Life Sciences has stopped developing WVE-004, an antisense drug built to silence the C9orf72 gene mutation behind both frontotemporal dementia and ALS, after a mid-stage trial found no clinical benefit despite clear biological activity.
A bill introduced in the Senate would credit hours spent bathing, medicating and transporting a relative with an age-related condition toward eligibility for bigger retirement contributions, but it is still sitting in committee with no vote scheduled.
H.R. 3747 would add dementia care to the list of specialty topics eligible for federal Project ECHO training grants and reauthorize the program through 2031, but it has not become law.
The Credit for Caring Act, reintroduced in the House and Senate in March 2025, would create a new federal tax credit of up to $5,000 for working family caregivers. More than a year later, the bipartisan bill remains in committee with no vote scheduled.
A peer-reviewed report on the second Healthy Brain Initiative Summit for Public Health Action describes state and local officials from 43 jurisdictions converging on shared dementia priorities, while naming continued federal funding as essential to keeping the effort moving.
The Administration for Community Living has posted a new round of federal grants for state respite care systems, including a companion track set aside specifically for dementia-specific respite programs, agency notices show.
The National Institute on Aging has published the finalized report from its fourth triennial Dementia Care and Caregiving Research Summit, naming five research areas and a list of gaps it wants filled next, including a fresh estimate that dementia now costs the country up to $800 billion a year.
A Nature Communications study in mice finds that a chemical tag on tau, a protein best known for forming Alzheimer's tangles, has a normal job: helping recruit the specific neurons that store a memory and helping those memories survive over weeks, not just days.
An op-ed in The Fulcrum argues aid-in-dying statutes are built for cancer timelines, not for capacity that goes first. It is an argument, not evidence, and the distinction matters.
Since July 1, 2026, residents of dedicated memory care units can no longer join the GUIDE Model, assisted living residents have lost access to its respite benefit, and providers must get CMS approval before signing new partnerships with residential care communities.